Oxfenicine
Based on 1 Customer Validation
Oxfenicine (L-p-Hydroxyphenylglycine) is an orally active carnitine palmitoyltransferase-1 inhibitor. Oxfenicine inhibits the oxidation of fatty acids in the heart, protecting cardiac tissue from necrotic damage during ischemia, and also has an inhibitory effect on cardiac tissue apoptosis. In addition, Oxfenicine promotes lipolysis in a high-fat diet rat model. Oxfenicine can be used in the study of cardiovascular and metabolic diseases.
For research use only. We do not sell to patients.
- Purity: 99.98%
- CAS No.: 32462-30-9
- Formula: C8H9NO3
- Molecular Weight:167.16
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Orally Active Compound Library
HY-L061
-
Lipid Metabolism Compound Library
HY-L091
-
Metabolic Enzyme Compound Library
HY-L146
-
Mitochondrial Toxicity Compound Library
HY-L155
-
Cell Death Library
HY-L162
-
MCE Bioactive Compound Library
HY-L001V
-
Non-natural Amino Acid Compound Library
HY-L198
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
3D Diverse Fragment Library
HY-L903
Biological Activity
carnitine palmitoyltransferase-1[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| KB | IC50 |
>100 μM
Compound: 46
|
Cytotoxicity in human KB cells
Cytotoxicity in human KB cells
|
[PMID: 21504156] |
Oxfenicine (1 mM, 2 hours) reduces fatty acid oxidation and glucose incorporation into lipids in subcutaneous and epididymal adipocytes[4]. Oxfenicine (10 mM, 24 hours) blunts carnitine plus palmitate-induced formation of apoptotic nuclei in chick embryonic ventricular cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Carnitine and Palmitate-induced chick embryonic ventricular cells (7-day-old chick embryos from white Leghorn eggs)
-
Concentration:10 mM
-
Incubation Time:24 h
-
Result:Significantly reduced the formation of apoptotic cell nuclei.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague-Dawley rats fed a high-fat (HF) diet[4]
-
Dosage:150 mg/kg
-
Administration:intraperitoneal injection (i.p.) once daily for 3 weeks
-
Result:Reduced whole-body fat oxidation, body weight, adiposity, and improved insulin sensitivity in HF-fed rats.
Chemical Information
-
CAS No. 32462-30-9
-
Appearance Solid
-
Molecular Weight 167.16
-
Formula C8H9NO3
-
Color White to off-white
-
SMILES
O=C([C@H](C1=CC=C(C=C1)O)N)O
-
Synonyms
L-p-Hydroxyphenylglycine; 4-Hydroxy-L-phenylglycine; UK 25842
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvent & Solubility
H2O : 4.55 mg/mL (27.22 mM; Need ultrasonic)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 2 mg/mL (11.96 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Stephens TW, et, al. Two mechanisms produce tissue-specific inhibition of fatty acid oxidation by oxfenicine. Biochem J. 1985 Apr 15;227(2):651-60. [Content Brief]
[2]. Greaves P, et, al. Cardiac hypertrophy in the dog and rat induced by oxfenicine, an agent which modifies muscle metabolism. Arch Toxicol Suppl. 1984;7:488-93. [Content Brief]
[3]. Kennedy JA, et al. Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart. J Cardiovasc Pharmacol. 2000 Dec;36(6):794-801. [Content Brief]
[4]. Sepa-Kishi DM, et al. Antilipolytic and antilipogenic effects of the CPT-1b inhibitor oxfenicine in the white adipose tissue of rats. Am J Physiol Regul Integr Comp Physiol. 2016 Oct 1;311(4):R779-R787. [Content Brief]
[5]. Kong JY, et al. Palmitate-induced cardiac apoptosis is mediated through CPT-1 but not influenced by glucose and insulin. Am J Physiol Heart Circ Physiol. 2002 Feb;282(2):H717-25. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 5.9823 mL | 29.9115 mL | 59.8229 mL | 149.5573 mL |
| 5 mM | 1.1965 mL | 5.9823 mL | 11.9646 mL | 29.9115 mL | |
| 10 mM | 0.5982 mL | 2.9911 mL | 5.9823 mL | 14.9557 mL | |
| 15 mM | 0.3988 mL | 1.9941 mL | 3.9882 mL | 9.9705 mL | |
| 20 mM | 0.2991 mL | 1.4956 mL | 2.9911 mL | 7.4779 mL | |
| 25 mM | 0.2393 mL | 1.1965 mL | 2.3929 mL | 5.9823 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Oxfenicine Related Classifications
HY-W018026 Related Classifications
Powered by Bioz